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ABSTRACT
Genetic, infectious and immune dysfunctions are 
implicated in the etiopathogenesis of Behget’s 
Syndrome (BS). Histopathological studies reveal 
mixed cellular infiltrations consisting of mostly T  
lymphocytes, m onocyte-m acrophages and 
neutrophils. Although a viral etiology is also 
suggested, atypical streptoccocci (Strep Sanguis, 
Salivarius etc) is the most investigated. Increased pro- 
inflammatory and Th1 type cytokines such as TN F-a, 
IFN-y, IL-2, IL-6 and IL-8 are found to be increased in 
the sera and in vitro culture supernatants. A 
controversial point is whether neutrophils are primarily 
defective (hyper-reactive) or activated due to the 
cytokine profile. Streptoccocal proteins such as KTH-1 
or 65 kD mycobacterial heat shock protein (HSP) and 
its cross-reactive human homologue are shown to 
cause T  and B cell responses in patients with BS. Both 
CD4+ and y8 T cells are activated with antigen-specific 
oligoclonal expansions and increased secretions of 
IFN-y, IL-8 and TN F-a. The link with HLA-B51 which is 
present as a susceptibility or a severity marker of BS, 
is suggested to be related to neutrophil hyperreactivity 
with increased neutrophil burst responses also in FILA- 
B51 transgenic animals. T cell responses to an HLA- 
B51 derived peptide and its retinal-S antigen 
homologue in posterior uveitis patients suggest that 
auto-immune responses might also be relevant. The 
same peptides are linked to uveitis also in rats and 
imply that different manifestations of BS may be
related to various and possibly organ-specific 
antigens.
Key Words: Behget’s Syndrome, Immune
response
Behget’s Syndrome (BS) is a multi-systemic disorder 
with muco-cutaneous, ocular, arthritic, vascular and 
central nervous system involvements. Recent 
developments in the etiopathogenesis of BS is 
discussed in this review.
Genetic Predisposition and HLA-B51
BS is mainly seen around Mediterranean Sea in a belt 
of countries extending from the Atlantic Ocean to 
Japan including Israel, Turkey, Iran, India, Korea and 
China (1). The prevelance is reported to be between 
1:250 to 1:10.000 in this region whereas it is reported 
to be 0.3-1:100.000 in USA and North Europe. The 
differences are not only reflected in prevelance but 
also in the severity of the cases. Most of the severe 
spectrum of BS such as uveitis, vascular and CNS 
involvement are mainly reported from countries where 
the disease is seen more frequently. Among various 
genetic markers, relationship to HLA class I antigens 
B5 and its split B51 is the most commonly reported
(2,3). The presence of this marker is reported to have
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a relative risk of 3-8 in different series. An important 
question is whether B51 is a marker of susceptibility or 
severity in BS. HLA B51 is found in only 50-60 % of the 
cases of BS suggesting that B51 is not required for the 
susceptibility to the disease. B51 may be related not to 
a general susceptibility of BS but to certain 
manifestations such as uveitis or vascular involvement 
as reported from UK (4). In terms of disease severity, 
although a high prevelance is found in hospital based 
populations (5), a field study of BS prevelance from 
Turkey found HLA B5 in only 26%  of the cases (6). 
Most of these cases were not diagnosed as BS before 
and had a mild disease spectrum. But in contrast with 
these observations, a recent report from Japan did not 
find higher ocular severity linked to B51(7). The 
spectrum of organ involvement in BS is studied mostly 
as the presence or absence of a certain manifestation 
such as uveitis or vascular involvement. As anterior 
and posterior uveitis have different ocular prognosis, 
with the latter generally causing irreversible vision 
loss, the role of B51 must be investigated with regard 
to posterior uveitis as a marker of severity.
The role of HLA class I antigens such as B51 is the 
presentation of endogenous antigens synthesized 
within the cell to CD8+ cytotoxic-suppressor T cells. 
The antigen specific region of B51 is analysed with the 
possible 8-10 amino acid length sequence of antigenic 
peptides reported (8). Among these peptides 
autoantigens such as thymidylate synthase (aa.253- 
61) or a yeast protein UBC5 (61-68) is present. The 
role of these HLA-B51 specific peptides and whether 
HLA B51 restricted CD 8+ T cells take a role in BS 
etiology is currently unknown. A recent animal model is 
also confusing as transgenic animals with HLA B51 did 
not develop the disease but only have neutrophil 
hyperreactivity in response to neutrophil activating 
agents like fMLP or PMA (9). The same group also 
observed an increased neutrophil burst activity in 
patients and healthy controls carrying HLA B51 which 
we could not confirm in our studies (10).
In addition to being a primary risk factor itself, HLA B51 
might be a marker of another gene positioned closely 
to B51 and is found on the same haplotype. Ohno et 
al. from Japan reported recently a MICA (M HC class I 
related-gene) between T N F -a  gene and HLA B region 
on chromosome 6 with a higher risk factor compared 
to HLA-B51 (11). But whether this marker which has a 
low heterogeneity is the real genetic predisposition to 
BS requires further studies in other ethnic groups.
Neutrophil hyperreactivity
As typical BS lesions such as pustular folliculitis, 
pathergy reactions and hypopyon has significant 
numbers of neutrophils, relationship of BS to 
neutrophil activation is pursued for a long time (1,3).
As neutrophils are a group of very mature cells with a 
very short life in vitro, their research is difficult, 
technically, reflecting the controversy in the literature 
over which activity best reflects neutrophil functions 
and is deregulated in BS. Various studies showed 
increased neutrophil chem otaxis, C>2 release, 
enzymatic activity and phagocytosis in active BS 
compared to healthy controls (9, 12-14), but the results 
are conflicting. M ege et al have shown increased basal 
C>2 production, but no differences in fMLP-stimulated  
neutrophils (12), Pronai et al. observed increased C>2 
both in stimulated or unstimulated neutrophils (13), 
whereas Takeno et al observed increased production 
only after fMLP stimulation (9). Neutrophil adhesion to 
endothelial cells is also reported to be both normal (14) 
or increased in BS with increased adhesion molecule 
expressions such as C D 11a and C D 18 (15). In 
addition, CD 10 and C D 14 two markers of neutrophil 
activation are also expressed higher on BS patients’ 
neutrophils (16). An interesting point is the occurrence 
of Behget's like symptoms in patients with chronic 
myeloid leukemia (CML) who are given interferon-a 
(IFN -a) treatment (17). In a controlled study, 24%  of 
these patients also developed pathergy test positivity
(18). As CML is a disease with a large number of 
mature neutrophils and their precursors in the blood, 
this effect of IF N -a  may be linked to neutrophil 
hyperreactivity.
One of the main problems in BS research is to 
distinguish between w hether BS neutrophils are 
primarily defective or whether soluble agents in BS 
serum or in local milieu, such as pro-inflammatory 
cytokines (IL-1, T N F -a , IL-6, IL-8 etc) released from 
activated mononuclear cells, are responsible for the 
neutrophil hyperreactivity (3, 19-21). As neutrophils in 
the active phases of BS are already activated when 
they are taken in vitro, this question is hard to answer. 
A better approach is to study the cases in complete 
remission but studies are very limited in this group and 
mostly negative.
Humoral immunity in BS
Although BS does not have the classical features of 
an auto-immune disease such as Sjogren's syndrome, 
fem ale dom inance, hypergam aglobulinem ia and 
autoantibodies such as anti-nuclear antibodies, some 
B cell activity such as increased spontaneous 
immunglobulin secretion is shown previously in BS 
(22). Some of the antibodies such as anti-endothelial 
cell or anti-cardiolipin antibodies are probably markers 
of endothelial dam age and activation in BS and not 
specific (23). Anti-65 kD mycobacterial heat shock 
protein (HSP) antibodies are more interesting as these 
are more frequently reported in linkage with infectious 
etiology (24, 25). In one study from Turkey, 48%  of 
neuro-BS patients compared to 12% of multiple
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sclerosis patients had increased levels of anti-65kD 
HSP antibodies in the cerebro-spinal fluid (26). B cells 
are recently studied also in detail in our Unit and 
although total B cell number was normal they were 
found to carry increased levels of activation markers 
such as CD13, CD33, C D 45R O  and CD80 (27). The 
distinction of BS from auto-immune disorders was also 
evident in this study in the low level of CD5+CD19+ B 
cells which are thought to produce auto-antibodies. As 
the role of B cells are not limited to antibody production 
as previously suggested, but also include antigen- 
presentation, their role in BS requires further study.
T cells in BS
Various observations suggest a significant contribution 
of T cells in BS. Pathergy reactions are either T cell 
dominated or have mixed infiltrates, as oral lesions, 
erythema nodosum and late stages of uveitis such as 
enucleated eyes (28, 29). Both CD4+ and CD8+ T 
cells producing Th1 type pro-inflammatory cytokines 
such as IL-2 and interferon-y are increased in 
peripheral blood (30). Recently C D 4+CD16+ and 
C D 4+C D 56+ T  cell subsets are also found to be 
increased in BS (31). An oligoclonal antigen-driven 
change in peripheral blood CD4 and CD8+ TCR V(i 
repertoire in patients with BS is also supportive of T 
cell participation (32). In addition to TCR a(3+ cells, 
TCR yô + cells are also increased in number in various 
studies {33, 34).
Antigenic stimulus in BS 
Streptoccocal antigens
T cells respond to exogenous or endogenous antigens 
presented by HLA class I or class II molecules on 
antigen presenting cells. Among the few antigens 
studied in detail in BS, bacterial microorganisms such 
as streptococci are the most implicated. KTH-1 (a 
crude extract or Streptoccocus sanguis SSH-83) is 
shown to cause increased IL-6 and interferon-y 
secretion from T cells of BS patients suggesting a role 
of this antigen in the pro-inflammatory response (35). 
KTH-1 is also shown to cause an Increase of y8 T  cells 
in BS patients after 9 day T cell cultures (36). Long 
term y5 T-cell lines produced by continuous stimulation 
with this antigen secrete pro-inflammatory cytokines 
such as IL-6, IL-8 and T N F -a  but no T-helper 2 type 
anti-inflammatory cytokines IL-4 and IL-10, supported 
by the low levels of IL-4 and IL-10 in the serum (37).
65 kD Heal Shock Protein
Another important candidate antigen for BS is 65 kD 
HSP and its peptide dérivâtes. HSPs are proteins 
which have a scavenger role for other intracellular
proteins under denaturating stress conditions such as 
infections, hypoxia and toxic drugs. They are highly 
conserved during evolution (mycobacterial and human 
65 kD HSPs have over 50%  homology). Although 
HSPs are part of the intra cellular protein transport 
mechanisms, 65 kD HSP is shown to be expressed on 
monocytes after interferon-y stimulation and also on T 
cells going apoptosis (38). These observations 
suggest that 60/65 kD HSPs might be ubiquitous 
antigens for the immune system. As significant 
sequence homology exists between mamalian and 
microbial HSPs, human HSP-responsive T cells 
stimulated by microbial counterparts (cross-reactivity) 
might trigger a longer T  cell memory, responsible for 
the chronicity of certain autoimmune or vasculitic 
disorders.
In a study by Ergun et al, in tissue specimens of 
pathergy reactions of BS patients, 65 kD HSP  
expression is found to be significantly higher 
compared to controls suggesting that it can also be a 
local antigen for BS (39). First in UK, then in Japan and 
in our Unit in Turkey, increased T  cell responses to 
mycobacterial and human 60/65 kD HSP are shown in 
the peripheral blood lymphocytes of BS patients 
compared to healthy controls (40-43). Although they 
are reported to be specific to be BS in UK and Japan, 
we observed a 18% positivity in our diseased controls 
(43).
Although yS T cell subset is reported to respond mainly 
to 60 kD HSP in UK, an oligoclonal increase in certain 
CD4+ TCR vp  subsets is reported from Japan in 
patients with uveitis after stimulation with HSP derived 
peptides. These HSP responsive T  cells are shown to 
release pro-inflammatory cytokines such as IL-6 and 
IL-8 and thought to participate in the inflammatory 
stimulus (42). Recently, by Saruhan-Direskeneli et al, 
PPD and 65 kD HSP specific T  cell lines are also found 
to be reactive to human 60 kD HSP derived peptides 
in both BS patients and healthy controls (44). An 
animal model in rats where certain human HSP 
derived peptides cause an uveitis but no other 
symptom of BS is also supportive of a role of HSP in 
BS (45).
Retinal>S Antigen and HLA-B51 -new 
autoantigens?
Another candidate antigen in BS is retinal-S antigen. 
This protein found mainly in the retina is accepted to 
be immune-priviledged and immune responses 
against it are found mainly after tissue destruction due 
to uveitis. T  cell responses against retinal-S antigen 
are found in various types of uveitis and are not 
specific to BS (46). Among various immuno-dominant 
epitopes of retinal-S antigen an epitope (aa 342-355) 
is found to share homology with a conserved region of
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HLA B molecules (aa 125-138) such as HLA-B51 and 
B27 which are linked to uveitis (47). This epitope Is 
shown to be recognized by CD 4+ T cells. This 
observation provoked a challenging theory of class I 
HLA molecules becoming antigenic epitopes 
themselves. Indeed, a significant portion of small 
peptides eluded from the surface of various HLA class 
II molecules are found to be HLA class I originated. As 
T cells recognizing class I antigens are a natural part 
of our immune repertoire but possibly tolerized in 
thymus, a break-down of tolerance is hypothesized to 
occur after uveal inflammation by cross-reactivity of 
retinal-S antigen reactive T  cells with HLA-reactive T 
cells. Development of uveitis in rats by both peptides is 
supportive of this observation. T cell responses to 
these peptides are shown in a small group of German 
uveitis patients and recently confirmed in a larger 
group of BS patients in our Unit (48). Interestingly, only 
T cells from patients with posterior uveitis but not with 
non-uveitis BS patients are responsive. This suggests 
that serious uvea destruction and activation of retinal- 
S antigen reactive T  cells is required for cross-reactive 
memory responses.
This theory provides another explanation for HLA B51 
participation in BS. Oral feeding of HLA B27/51 
derived peptide is shown to prevent retinal-S antigen 
uveitis in animal models and is now tried in refractory 
human uveitis patients as a way of treatment with oral 
tolerance (49).
Observations from the clinical trials: 
different antigenic stimuli for 
different manifestations?
Different manifestations of BS occurring during the 
course of the disease unpredictably and unlinked to 
any previous risk factor suggests that various, possibly 
organ-specific antigens might be responsible for BS. 
Therapy studies support this observation as the effects 
of various popular treatments in BS seems to be 
organ-specific. Colchicine is especially effective for 
erythema-nodosum (EN) like lesions but has a limited 
effect on uveitis. On the other hand, in a recently 
published double-blind controlled trial thalidomide was 
effective for oral and genital ulcers, but caused a 
significant increase in EN lesions in the first 8 weeks
(50). As an explanation for this suprising observation, 
Hamuryudan et al. suggest that “the cause of aphthous 
ulcers and EN may not have a common putative 
denominator in BS”.
T cell responses to HLA-B and retinal-S antigen 
derived peptides only in posterior uveitis patients 
mentioned above may also support this hypothesis. 
Immune responses to local antigens such as dermal 
keratins in psoriasis or synovial antigens such as
collagen type II in rheumatoid arthritis were reported 
previously. Similarly, local antigens might be relevant 
for patient subgroups with muco-cutaneous or articular 
organ involvements in BS. Better characterization and 
immuno-modulation of these local antigens may help 
to develop more specific and less toxic 
im m unotherapeutic approaches to this still 
unsatisfactorily treated disease.
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